Clinical Trial

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Participants will: Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals
Trial Details
NCT Number NCT07244393
Lead Sponsor Cellbion Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC
Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment 30 participants
Start Date 2025-12
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-24